The PTCB study guide — updated for the 2026 PTCE
Updated
The complete guide, free on this page — organized by the four current blueprint domains, with the exact outline codes, sourced tables, and a five-question check at the end of every chapter. No premium locks mid-section, ever.
What changed on 2026-01-06
New weights — Medications 35% · Federal Requirements 18.75% · Patient Safety & Quality Assurance 23.75% · Order Entry & Processing 22.5%. Added: DSCSA track-and-trace, drug take-back programs, drug stability. Removed: alligation, NTI medications, non-sterile compounding. Many guides still teach the 2020 outline — verify against the official PDF.
Medications
35% of the exam
| Code | Knowledge area |
|---|---|
| 1.1 | Names, brands & classes |
| 1.2 | Therapeutic duplication |
| 1.3 | Interactions & contraindications |
| 1.4 | Doses, forms & routes |
| 1.5 | Side effects & allergies |
| 1.6 | Indications |
| 1.7 | Drug stability |
| 1.8 | Storage requirements |
The biggest domain rewards structured recall: names and classes (1.1), what a drug is for (1.6), what it clashes with (1.2, 1.3), what it does to patients (1.5), and how it lives on a shelf (1.4, 1.7, 1.8). Learn classes before drugs — one suffix unlocks ten names — then attach indications and warnings to the class, not the molecule.
Suffixes → classes: the highest-yield table in the domain
| Suffix | Class | Example |
|---|---|---|
| -pril | ACE inhibitor | lisinopril |
| -sartan | ARB (angiotensin receptor blocker) | losartan |
| -olol | Beta blocker | metoprolol |
| -dipine | Calcium channel blocker (dihydropyridine) | amlodipine |
| -statin | HMG-CoA reductase inhibitor | rosuvastatin |
| -prazole | Proton pump inhibitor | pantoprazole |
| -tidine | H2 blocker | famotidine |
| -azole | Azole antifungal | fluconazole |
| -floxacin | Fluoroquinolone antibiotic | ciprofloxacin |
| -cillin | Penicillin-class antibiotic | amoxicillin |
| -cycline | Tetracycline-class antibiotic | doxycycline |
| -triptan | Serotonin agonist (migraine) | sumatriptan |
| -gliptin | DPP-4 inhibitor (diabetes) | sitagliptin |
| -glutide | GLP-1 receptor agonist | semaglutide |
| -gliflozin | SGLT2 inhibitor | empagliflozin |
| -setron | 5-HT3 antiemetic | ondansetron |
| -pam / -lam | Benzodiazepine | lorazepam |
| -osin | Alpha-1 blocker (BPH) | tamsulosin |
| -lukast | Leukotriene receptor antagonist | montelukast |
| -dronate | Bisphosphonate | alendronate |
Source: Cross-checked against the RxNorm/RxClass-verified top-200 dataset · verified 2026-08-03
Interaction families the exam actually tests (1.2, 1.3)
Scenario questions cluster around a handful of mechanisms: two drugs that both thin blood (anticoagulant + NSAID), two that both depress breathing (opioid + benzodiazepine), two that both raise serotonin, duplicated therapy inside one class (two NSAIDs — the classic 1.2 item), and grapefruit or azole antifungals boosting a statin. When a stem lists two drugs, ask “what do these have in common?” — the overlap IS the answer.
Storage, stability, and the cold chain (1.4, 1.7, 1.8)
| Condition | Range | Exam angle |
|---|---|---|
| Refrigerated | 2–8 °C (36–46 °F) | Insulin stock, many vaccines, reconstituted amoxicillin |
| Controlled room temperature | 20–25 °C (68–77 °F) | Most solid orals; insulin IN USE (per label, commonly 28 days) |
| Freezer | −25 to −10 °C | A handful of vaccines — never insulin |
| Light-protected / restricted access | per label · C-II vault or dispersal | Nitroglycerin amber glass; controlled-substance storage |
Stability (1.7) is NEW emphasis on the 2026 outline: reconstituted suspensions carry short beyond-use dates, insulin in use follows the label’s day count, and anything past its BUD is a non-dispensable return — storage ranges above follow USP packaging-and-storage conventions; the label always wins.
Prove the chapter — 5 questions
Question 1 of 5
0 answered · 0 flagged
Which product should a patient separate from a doxycycline dose because it binds the antibiotic and blocks absorption?
Federal Requirements
18.75% of the exam
| Code | Knowledge area |
|---|---|
| 2.1 | Hazardous handling & disposal |
| 2.2 | Controlled prescriptions & DEA schedules |
| 2.3 | Controlled-substance operations |
| 2.4 | Restricted drug programs |
| 2.5 | FDA recalls |
| 2.6 | DSCSA track & trace |
The smallest domain, and the most memorizable: hazardous handling (2.1), controlled substances end to end (2.2, 2.3), restricted programs (2.4), recalls (2.5), and the supply chain (2.6). Every fact below was checked against the current CFR or FDA text.
DEA schedules (2.2)
| Schedule | Definition | Examples |
|---|---|---|
| C-I | No accepted medical use in the US; highest abuse potential — not dispensed by pharmacies | heroin, LSD, marijuana (federal) |
| C-II | Accepted medical use, high abuse potential; no refills, written/electronic Rx rules | oxycodone, hydrocodone, fentanyl, morphine, amphetamine salts |
| C-III | Moderate physical / high psychological dependence risk; ≤5 refills in 6 months | buprenorphine, ketamine, acetaminophen with codeine, anabolic steroids |
| C-IV | Lower abuse potential than III; ≤5 refills in 6 months | alprazolam, lorazepam, zolpidem, tramadol, carisoprodol |
| C-V | Lowest abuse potential of the scheduled drugs; some sold with restrictions | pregabalin, diphenoxylate/atropine, some codeine cough preparations |
Source: 21 CFR 1308 (schedules) · verified 2026-08-03
DEA forms (2.3)
| Form | Purpose | Exam angle |
|---|---|---|
| DEA Form 222 | Ordering Schedule I–II substances (paper or CSOS electronic equivalent) | 222 = C-II ordering; C-III–V need only an invoice |
| DEA Form 224 | Pharmacy application to register with DEA to dispense controlled substances | 224 = the pharmacy's registration itself |
| DEA Form 41 | Recording destruction of controlled substances | 41 = destruction record (reverse distributors, 21 CFR 1317) |
| DEA Form 106 | Reporting theft or significant loss of controlled substances | 106 = theft/loss, filed after notifying the DEA within one business day |
Source: 21 CFR 1305 (Form 222/CSOS) · verified 2026-08-03
Recall classes (2.5)
| Class | Meaning |
|---|---|
| Class I | Reasonable probability of serious harm or death — the urgent one |
| Class II | May cause temporary or reversible harm; serious harm unlikely |
| Class III | Unlikely to cause harm — labeling/quality defects |
| Market withdrawal | Minor issue or tampering without recall grounds — firm's own action |
Source: FDA — recall definitions · verified 2026-08-03
The legislation timeline
| Year | Act | What it did | Exam angle |
|---|---|---|---|
| 1906 | Pure Food and Drug Act | Prohibited interstate commerce in adulterated or misbranded food and drugs | Adulteration vs misbranding starts here |
| 1938 | Food, Drug, and Cosmetic Act | Required drugs to be proven SAFE before marketing; created the modern FDA framework | Safety first — efficacy came later (1962) |
| 1951 | Durham-Humphrey Amendment | Defined prescription (legend) vs over-the-counter drugs; restricted Rx drugs to prescriber orders | "Rx only" legend; verbal Rx + refills recognized |
| 1962 | Kefauver-Harris Amendments | Required proof of EFFECTIVENESS before marketing (post-thalidomide) | Efficacy + safety; retroactive drug review |
| 1970 | Controlled Substances Act | Categorized drugs into schedules by abuse potential vs therapeutic value | The five schedules; DEA enforcement |
| 1970 | Poison Prevention Packaging Act | Required child-resistant packaging for most oral prescription drugs | Know the common exemptions (e.g., nitroglycerin) and waiver rules |
| 1988 | Prescription Drug Marketing Act | Banned diversion, sample sale/trade, and required state wholesaler licensing | Samples can never be sold |
| 1990 | OBRA-90 | Required DUR programs and an OFFER to counsel Medicaid patients (states extended it broadly) | The counseling offer — techs relay, pharmacists counsel |
| 1996 | HIPAA | Protected identifiable health information (PHI) privacy and security | Minimum necessary; PHI disposal |
| 2005 | Combat Methamphetamine Epidemic Act | Put daily/30-day limits, logbooks, and behind-the-counter rules on pseudoephedrine sales | 3.6 g/day · 9 g/30 days · logbook 2 years |
| 2013 | DSCSA (Drug Quality and Security Act, Title II) | Built the electronic, interoperable package-level track-and-trace system | NEW on the 2026 outline: product identifiers, transaction data, quarantine of suspect product |
Source: FDA — Milestones in US food and drug law · verified 2026-08-03
DSCSA (2.6) is the 2026outline’s headline addition: package-level product identifiers, transaction data between authorized trading partners, and quarantine-then-investigate for suspect product. Most prep sites still don’t cover it; the quiz bank here has a full DSCSA area.
Prove the chapter — 5 questions
Question 1 of 5
0 answered · 0 flagged
A pharmacy's Schedule II order comes back unfilled because a quantity had been erased and rewritten. What was the supplier required to do?
Patient Safety & Quality Assurance
23.75% of the exam
| Code | Knowledge area |
|---|---|
| 3.1 | High-alert & look-alike drugs |
| 3.2 | Error-prevention strategies |
| 3.3 | Pharmacist-intervention triggers |
| 3.4 | Event reporting |
| 3.5 | Prescription-error types |
| 3.6 | Infection prevention |
The second-largest domain tests systems, not trivia: which drugs deserve extra process (3.1), how errors are prevented structurally (3.2), when the pharmacist must step in (3.3), where events get reported (3.4), how errors are classified (3.5), and hygiene standards (3.6).
High-alert classes (3.1)
| Class | Why it's high-alert |
|---|---|
| Insulin (all formulations) | Unit/concentration confusion; U-100 vs U-500; never abbreviate "U" |
| Anticoagulants (heparin, warfarin, DOACs) | Narrow margin — bleeding; heparin concentration mix-ups |
| Opioids | Respiratory depression; patch strengths; look-alike names |
| Concentrated electrolytes (KCl injection) | Fatal if given undiluted — stored away from floor stock |
| Chemotherapeutic agents | Low therapeutic index; weekly-vs-daily errors (oral methotrexate) |
| Neuromuscular blocking agents | Paralyze breathing — catastrophic outside ventilated patients |
| Moderate sedation agents | Airway compromise risk outside monitored settings |
| Epidural / intrathecal medications | Route errors are frequently fatal |
Source: ISMP — list of high-alert medications in acute care settings (2024) · verified 2026-08-03
LASA pairs with Tall Man lettering (3.1, 3.2)
| Pair | Why it's dangerous | |
|---|---|---|
| hydrOXYzine | hydrALAZINE | antihistamine vs antihypertensive |
| predniSONE | prednisoLONE | different potency — not interchangeable mg-for-mg |
| glipiZIDE | glyBURIDE | both sulfonylureas — different durations, hypoglycemia risk |
| buPROPion | busPIRone | antidepressant vs anxiolytic |
| DOPamine | DOBUTamine | different hemodynamic effects |
| ALPRAZolam | LORazepam | benzodiazepine pair — dosing differs |
| carBAMazepine | OXcarbazepine | related anticonvulsants, different doses |
| vinBLAStine | vinCRIStine | chemotherapy pair — mix-ups have been fatal |
| cefTRIAXone | ceFAZolin | different-generation cephalosporins |
| chlorproMAZINE | chlordiazePOXIDE | antipsychotic vs benzodiazepine |
Source: FDA and ISMP — look-alike drug names with recommended tall man letters (ISMP resource, ECRI-hosted) · verified 2026-08-03
Prevention mechanics the exam names (3.2, 3.5)
| Mechanism | The rule |
|---|---|
| Leading zeros | Always 0.5 mg — a naked .5 reads as 5 (10× error) |
| Trailing zeros | Never 5.0 mg — reads as 50 |
| Tall Man lettering | Capitalize the differing letters in LASA names |
| Separated inventory | High-alert and LASA stock stored apart, flagged on shelf |
| Barcode scanning | NDC-level verification at filling — catches wrong-drug/wrong-strength |
| Error taxonomy (3.5) | Wrong patient, drug, dose, quantity, or route — name which one the scenario shows |
Source: FDA and ISMP — look-alike drug names with recommended tall man letters (ISMP resource, ECRI-hosted) · verified 2026-08-03
Who gets the report (3.4)
| Program | Run by | What to report |
|---|---|---|
| MedWatch | FDA | Serious adverse events, product quality problems, therapeutic failures |
| VAERS | CDC + FDA | Adverse events after vaccination |
| ISMP MERP | ISMP (voluntary, confidential) | Medication errors and near misses, to drive system fixes |
Source: FDA MedWatch · verified 2026-08-03
Pharmacist-intervention triggers (3.3): DUR alerts, adverse-event reports, OTC recommendations, therapeutic substitution, suspected misuse, adherence problems, post-immunization reactions, and any new allergy or interaction flag. The tech’s job is recognizing the trigger and routing it — never resolving it. Infection prevention (3.6) is process hygiene: hand-washing between patients, PPE for compounding, and cleaning counting trays (notably after penicillins) and counters on schedule.
Prove the chapter — 5 questions
Question 1 of 5
0 answered · 0 flagged
A profile shows a documented penicillin allergy, and a new amoxicillin prescription triggers an alert. Which prospective DUR category fired?
Order Entry & Processing
22.5% of the exam
| Code | Knowledge area |
|---|---|
| 4.1 | Calculations & sig codes |
| 4.2 | Administration equipment & supplies |
| 4.3 | NDC, lot & expiration |
| 4.4 | Returns & non-dispensable stock |
Where the math lives (4.1 — drilled in the calculations chapter below), plus the physical goods: administration supplies (4.2), package identity (4.3), and what may go back on the shelf (4.4).
Sig codes — the high-yield dozen (4.1)
| Code | Meaning | ISMP note |
|---|---|---|
| QD | once daily | Mistaken as q.i.d. when the tail of a handwritten q reads as an i — ISMP 2024 |
| BID | twice daily | — |
| TID | three times daily | — |
| QID | four times daily | — |
| QHS | at bedtime | — |
| PRN | as needed | — |
| AC | before meals | — |
| PC | after meals | — |
| PO | by mouth | — |
| HS | at bedtime | — |
| OD | right eye | Mistaken for AD (right ear) or 'once daily' — ISMP |
Source: ISMP error-prone abbreviations list (ECRI-hosted) + PTCE outline area 4.1 · verified 2026-08-03
NDC structure (4.3)
FDA assigns a 10-digit NDC in 4-4-2, 5-3-2, or 5-4-1; billing systems pad a zero to a standardized 11-digit 5-4-2.
| Segment | Identifies |
|---|---|
| Labeler (first 4–5 digits) | The manufacturer, repackager, or distributor — FDA-assigned |
| Product (middle 3–4 digits) | Specific drug, strength, and dosage form |
| Package (last 1–2 digits) | Package size and type |
Source: FDA — format of the National Drug Code · verified 2026-08-03
DAW codes (4.1)
| Code | Meaning |
|---|---|
| 0 | No product selection indicated — substitution permitted (the default) |
| 1 | Substitution not allowed by prescriber ("dispense as written") |
| 2 | Substitution allowed — patient requested the brand |
| 3 | Substitution allowed — pharmacist selected the brand |
| 4 | Substitution allowed — generic not in stock |
| 5 | Substitution allowed — brand dispensed but priced as generic |
| 6 | Override |
| 7 | Substitution not allowed — brand mandated by law |
| 8 | Substitution allowed — generic not commercially available |
| 9 | Substitution allowed — plan requests the brand |
Source: NCPDP — telecommunication standard DAW values (white paper) · verified 2026-08-03
Returns (4.4): sealed, in-date stock that never left the pharmacy may return to shelf; anything dispensed to a patient, expired, or recalled routes to reverse distribution or quarantine — never back to stock. Lot number + expiration travel with every return decision (4.3), which is why the exam pairs those two areas.
Prove the chapter — 5 questions
Question 1 of 5
0 answered · 0 flagged
A 50 mL vial of lidocaine 0.5% with epinephrine 1:200,000 is on the shelf. How many mg of epinephrine does it contain?
Calculations — the cluster that decides pass/fail
cross-domain| Code | Knowledge area |
|---|---|
| 1.4 | Doses, forms & routes |
| 4.1 | Calculations & sig codes |
| 4.2 | Administration equipment & supplies |
Calculation items concentrate in areas 1.4, 4.1, and 4.2 and behave differently from recall: they’re slow, they chain, and they punish setup errors. These two worked examples come straight from the engine that generates the trainer’s infinite stream — every number recomputes, every step lands on the answer.
A prescription for amoxicillin 500 mg is filled with 20 capsules. The sig reads: "Take 1 capsule PO BID (twice daily)." What is the days supply?
1 capsule × 2 times/day = 2/dayMultiply the dose per administration by administrations per day to get daily usage.20 ÷ 2 = 10Divide the quantity dispensed by daily usage to get the days supply.
Answer10 days
Generated + verified by the math engine — every number recomputes
An IV of 1000 mL 0.9% sodium chloride (NS) is to infuse over 24 hours using tubing with a drop factor of 60 gtt/mL. What is the drip rate in gtt/min?
24 hr × 60 = 1440 minDrip rates are per minute — convert the infusion time to minutes.1000 mL × 60 gtt/mL = 60000 gttMultiply volume by the tubing's drop factor to get total drops.60000 gtt ÷ 1440 min = 41.67 gtt/minDivide total drops by total minutes.round(41.67) = 42Drops can't be split — round to the nearest whole drop per minute.
Answer42 gtt/min
Generated + verified by the math engine — every number recomputes
The conversions to burn in
The full chart (with worked trap rows and the printable) lives on the conversions page; the must-memorize set is marked row by row. Exact factors per NIST SP 811.
| Group | Rows to memorize |
|---|---|
| Metric — mass | 1 kg · 1 g · 1 mg |
| Metric — volume | 1 L |
| Household | 1 teaspoon (tsp) · 1 tablespoon (tbsp) · 1 fluid ounce (fl oz) · 1 cup · 1 pint |
| Body weight & avoirdupois | 1 kg |
| Apothecary (legacy) | 1 grain (gr) |
| Temperature | °F → °C · °C → °F |
| Roman numerals (sig usage) | ss · i · v · x |
Where this guide fits among the options
| Resource | Cost | Honest read |
|---|---|---|
| This guide + quizzes | Free | Current 2026 outline, sourced tables, practice attached to every chapter — draft bank pending CPhT review |
| Official PTCB tools | $65 bank · $29 Pre-PTCE | Real former exam questions from the exam owner; no teaching layer — best used as a final check |
| Prep books (Mometrix, Ascencia…) | ≈$20–40 | Structured and portable; verify the blueprint edition before buying — many still print 2020 weights |
| Shared docs & forums | Free | Motivating, occasionally brilliant, unverified — and mostly written before the 2026 change |
Official prices: ptcb.org
Printable PDF
The 2026 guide as a PDF
Every chapter, table, and worked example on this page — typeset for print. The canonical version of the doc everyone asks for.
Common questions
What is the best way to study for the PTCB exam?
Diagnose, then drill: take one full-length blueprint-weighted practice exam to find your weakest domain, work that chapter and its quiz until the misses stop, and re-test. Reading cover-to-cover feels productive but hides your gaps — the domains are weighted 35% / 18.75% / 23.75% / 22.5%, so study time should be too.
Is the PTCB exam hard?
69% of attempts passed in 2025 — most peoplepass, roughly a third don’t. The failures cluster in one neglected domain (usually math or law) rather than overall difficulty, which is why every chapter here ends with a self-check instead of a pep talk.
How long should you study for the PTCB?
Four to eight weeks of consistent one-hour sessions works for most candidates with pharmacy work or coursework behind them; from scratch, plan eight to twelve. The honest answer comes from data: take the free diagnostic first and let your scaled estimate set the timeline.